FDA Approves Breyanzi for Marginal Zone Lymphoma

The FDA just approved the first CAR-T therapy for a rare blood cancer that had

almost no treatment options. Breyanzi is now available for marginal zone lymphoma patients

who've tried at least two other treatments. Here's what's wild: in clinical trials,

95.5% of patients responded to this one-time treatment. Your own immune cells get collected,

engineered to hunt cancer, then put back in your body. Nearly every patient

saw their cancer shrink or disappear. Even better, 90% stayed in remission after two

years. This personalized living drug is changing how we fight rare cancers,

giving hope where there wasn't any before. Follow us and visit our website